EHA26: AstraZeneca battles Roche in untreated follicular lymphoma
At the 2026 European Hematological Association (EHA) conference, held in Stockholm on 11–14 June, AstraZeneca shared preliminary safety…
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
F. Hoffmann-La Roche Ltd Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus…
India gets first approved precision treatment for advanced prostate cancer. How Pluvicto works
New Delhi: Introducing India’s first regulatory authority-approved radioligand therapy for advanced prostate cancer, Swiss pharmaceutical company Novartis on…
Roche’s Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
Roche RHHBY announced that the FDA has granted priority review to its supplemental biologics license application (sBLA), seeking…
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
F. Hoffmann-La Roche Ltd Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus…
Roche-Nurix $2.3B Licensing Agreement for Bexobrutideg: BTK Degrader for Blood Cancers – News and Statistics
Jun 8, 2026 Roche Holding has entered into a licensing agreement with Nurix Therapeutics for an experimental blood-cancer…